ALX ONCOLOGY HOLDINGS INC
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
ALXO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US00166B1052
- LEI:
- Country:
- United States of America
- Address:
- 323 ALLERTON AVENUE, 94080 SOUTH SAN FRANCISCO
- Website:
- https://alxoncology.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that harness the immune system to combat cancer. The company's lead therapeutic candidate, evorpacept, is a next-generation CD47 checkpoint inhibitor designed to block a key signal that cancer cells use to evade immune detection. ALX Oncology is advancing evorpacept in multiple clinical trials as a potential cornerstone therapy for use in combination with other anti-cancer agents. The company's development pipeline targets a broad range of hematologic malignancies and solid tumors, with the goal of improving upon current and future standards of care for cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ALX ONCOLOGY HOLDINGS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALX ONCOLOGY HOLDINGS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALX ONCOLOGY HOLDINGS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
